Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas

M. Trottier, J. Lunn, R. Butler, D. Curling, T. Turnquest, W. Francis, D. Halliday, R. Royer, S. Zhang, S. Li, I. Thompson, T. Donenberg, Judith Hurley, M. R. Akbari, S. A. Narod

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Population-based testing for BRCA1/2 mutations detects a high proportion of carriers not identified by cancer family history-based testing. We sought to determine whether population-based testing is an effective approach to genetic testing in the Bahamas, where 23% of women with breast cancer carry one of seven founder mutations in the BRCA1 or BRCA2 gene. We determined the prevalence of founder BRCA mutations in 1847 Bahamian women without a personal history of breast or ovarian cancer, unselected for age or family history. We found that 2.8% (20/705) of unaffected women with a family history of breast/ovarian cancer and 0.09% (1/1089) of unaffected women without a family history carry a BRCA mutation. A total of 38% of unaffected women with a known mutation in the family were found to carry the familial mutation. We previously suggested that all Bahamian women with breast or ovarian cancer be offered genetic testing. These current data suggest that additionally all unaffected Bahamian women with a family history of breast/ovarian cancer should be offered genetic testing for the founder BRCA mutations.

Original languageEnglish (US)
Pages (from-to)328-331
Number of pages4
JournalClinical Genetics
Volume89
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Bahamas
BRCA2 Gene
BRCA1 Gene
Mutation
Ovarian Neoplasms
Breast Neoplasms
Genetic Testing
Population

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • Genetic testing
  • Population genetic screening

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Trottier, M., Lunn, J., Butler, R., Curling, D., Turnquest, T., Francis, W., ... Narod, S. A. (2016). Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clinical Genetics, 89(3), 328-331. https://doi.org/10.1111/cge.12602

Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. / Trottier, M.; Lunn, J.; Butler, R.; Curling, D.; Turnquest, T.; Francis, W.; Halliday, D.; Royer, R.; Zhang, S.; Li, S.; Thompson, I.; Donenberg, T.; Hurley, Judith; Akbari, M. R.; Narod, S. A.

In: Clinical Genetics, Vol. 89, No. 3, 01.03.2016, p. 328-331.

Research output: Contribution to journalArticle

Trottier, M, Lunn, J, Butler, R, Curling, D, Turnquest, T, Francis, W, Halliday, D, Royer, R, Zhang, S, Li, S, Thompson, I, Donenberg, T, Hurley, J, Akbari, MR & Narod, SA 2016, 'Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas', Clinical Genetics, vol. 89, no. 3, pp. 328-331. https://doi.org/10.1111/cge.12602
Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Francis W et al. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clinical Genetics. 2016 Mar 1;89(3):328-331. https://doi.org/10.1111/cge.12602
Trottier, M. ; Lunn, J. ; Butler, R. ; Curling, D. ; Turnquest, T. ; Francis, W. ; Halliday, D. ; Royer, R. ; Zhang, S. ; Li, S. ; Thompson, I. ; Donenberg, T. ; Hurley, Judith ; Akbari, M. R. ; Narod, S. A. / Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. In: Clinical Genetics. 2016 ; Vol. 89, No. 3. pp. 328-331.
@article{8b61a43644f549e5bc13bafcc7de6569,
title = "Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas",
abstract = "Population-based testing for BRCA1/2 mutations detects a high proportion of carriers not identified by cancer family history-based testing. We sought to determine whether population-based testing is an effective approach to genetic testing in the Bahamas, where 23{\%} of women with breast cancer carry one of seven founder mutations in the BRCA1 or BRCA2 gene. We determined the prevalence of founder BRCA mutations in 1847 Bahamian women without a personal history of breast or ovarian cancer, unselected for age or family history. We found that 2.8{\%} (20/705) of unaffected women with a family history of breast/ovarian cancer and 0.09{\%} (1/1089) of unaffected women without a family history carry a BRCA mutation. A total of 38{\%} of unaffected women with a known mutation in the family were found to carry the familial mutation. We previously suggested that all Bahamian women with breast or ovarian cancer be offered genetic testing. These current data suggest that additionally all unaffected Bahamian women with a family history of breast/ovarian cancer should be offered genetic testing for the founder BRCA mutations.",
keywords = "BRCA1, BRCA2, Breast cancer, Genetic testing, Population genetic screening",
author = "M. Trottier and J. Lunn and R. Butler and D. Curling and T. Turnquest and W. Francis and D. Halliday and R. Royer and S. Zhang and S. Li and I. Thompson and T. Donenberg and Judith Hurley and Akbari, {M. R.} and Narod, {S. A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/cge.12602",
language = "English (US)",
volume = "89",
pages = "328--331",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas

AU - Trottier, M.

AU - Lunn, J.

AU - Butler, R.

AU - Curling, D.

AU - Turnquest, T.

AU - Francis, W.

AU - Halliday, D.

AU - Royer, R.

AU - Zhang, S.

AU - Li, S.

AU - Thompson, I.

AU - Donenberg, T.

AU - Hurley, Judith

AU - Akbari, M. R.

AU - Narod, S. A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Population-based testing for BRCA1/2 mutations detects a high proportion of carriers not identified by cancer family history-based testing. We sought to determine whether population-based testing is an effective approach to genetic testing in the Bahamas, where 23% of women with breast cancer carry one of seven founder mutations in the BRCA1 or BRCA2 gene. We determined the prevalence of founder BRCA mutations in 1847 Bahamian women without a personal history of breast or ovarian cancer, unselected for age or family history. We found that 2.8% (20/705) of unaffected women with a family history of breast/ovarian cancer and 0.09% (1/1089) of unaffected women without a family history carry a BRCA mutation. A total of 38% of unaffected women with a known mutation in the family were found to carry the familial mutation. We previously suggested that all Bahamian women with breast or ovarian cancer be offered genetic testing. These current data suggest that additionally all unaffected Bahamian women with a family history of breast/ovarian cancer should be offered genetic testing for the founder BRCA mutations.

AB - Population-based testing for BRCA1/2 mutations detects a high proportion of carriers not identified by cancer family history-based testing. We sought to determine whether population-based testing is an effective approach to genetic testing in the Bahamas, where 23% of women with breast cancer carry one of seven founder mutations in the BRCA1 or BRCA2 gene. We determined the prevalence of founder BRCA mutations in 1847 Bahamian women without a personal history of breast or ovarian cancer, unselected for age or family history. We found that 2.8% (20/705) of unaffected women with a family history of breast/ovarian cancer and 0.09% (1/1089) of unaffected women without a family history carry a BRCA mutation. A total of 38% of unaffected women with a known mutation in the family were found to carry the familial mutation. We previously suggested that all Bahamian women with breast or ovarian cancer be offered genetic testing. These current data suggest that additionally all unaffected Bahamian women with a family history of breast/ovarian cancer should be offered genetic testing for the founder BRCA mutations.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Genetic testing

KW - Population genetic screening

UR - http://www.scopus.com/inward/record.url?scp=84958124506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958124506&partnerID=8YFLogxK

U2 - 10.1111/cge.12602

DO - 10.1111/cge.12602

M3 - Article

C2 - 25920394

AN - SCOPUS:84958124506

VL - 89

SP - 328

EP - 331

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -